Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic

Hepatology Communications

Volumn 1, Issue 7, 2017, Pages 577-585

  Filozof, Claudia ^a   Chow, Shein Chung ^b   Dimick Santos, Lara ^c   Chen, Yeh Fong ^c   Williams, Richard N ^d   Goldstein, Barry J ^d   Sanyal, Arun ^e  

^a Covance Clinical Development Services ^*  (United Kingdom)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d 206 Carnegie Center   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL OUTCOME; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE COURSE; DRUG DEVELOPMENT; EPIDEMIC; HUMAN; LIVER BIOPSY; LONG TERM EXPOSURE; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; UNCERTAINTY; VALIDITY;

EID: 85038900801     PISSN: None     EISSN: 2471254X     Source Type: Journal    
DOI: 10.1002/hep4.1079     Document Type: Review

References (31)

1. Sanyal AJ. NASH: A global health problem. Hepatol Res 2011;41:670-674.
2. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524-530.e1.
3. Filozof C, Goldstein BJ, Williams RN, Sanyal A. Non-alcoholic steatohepatitis: limited available treatment options but promising drugs in development and recent progress towards a regulatory approval pathway. Drugs 2015;75:1373-1392.
4. Misra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep 2009;11:50-55.
5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global Epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 2016;64:73-84.
6. Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology 2016;64:1969-1977.
7. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-397.e10.
8. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases; United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration joint workshop. Hepatology 2015;61:1392-1405.
9. Sanyal A, Brunt E, Kleiner D, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-353.
10. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-1217.
11. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
12. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53:810-820.
13. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-54.e1-9.
14. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009;51:371-379.
15. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017;65:1557-1565.
16. ClinicalTrials.gov. Phase 3 study to evaluate the efficacy and safety of elafibranor versus placebo in patients with nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT). https://clinicaltrials.gov/ct2/show/NCT02704403?term=genfit&rank=3. Accessed October 2016.
17. ClinicalTrials.gov. Randomized global phase 3 study to evaluate the impact on NASH with fibrosis of obeticholic acid treatment (REGENERATE). https://clinicaltrials.gov/ct2/show/NCT02548351?term=intercept+NASH&rank=1. Accessed October 2016.
18. Guidance for Industry. Adaptive design clinical trials for drugs and biologics. Food and Drug Administration. February 2010. Available at: http://www.fda.gov/downloads/Drugs/../Guidances/ucm201790.pdf.
19. Chow SC, Lin M. Analysis of two-stage adaptive seamless trial design. Pharm Anal Acta 2015;6:341.
20. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Guidance for industry expedited programs for serious conditions – drugs and biologics. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf. Published May 30, 2014.
21. European Medicines Agency launches adaptive licensing pilot project [press release]. European Medicines Agency/430892/2013; March 19, 2014. Available at: www.ema.europa.eu.
22. Chow SC, Tu YH. On two-stage seamless adaptive design in clinical trials. J Formos Med Assoc 2008;107(12 Suppl.):52-60.
23. Chow SC, Corey R. Benefits, challenges and obstacles of adaptive clinical trial designs. Orphanet J Rare Dis 2011;6:79.
24. Lu Q, Chow SC, Tse SK, Chi Y, Yang LY. Sample size estimation based on event data for a two-stage survival adaptive trial with different durations. J Biopharm Stat 2009;19:311-323.
25. Lu Q, Tse SK, Chow SC. Analysis of time-to-event data under a two-stage survival adaptive design in clinical trials. J Biopharm Stat 2010;20:705-719.
26. Lu Q, Tse SK, Chow SC, Lin M. Analysis of time-to-event data with nonuniform patient entry and loss to follow-up under a two-stage seamless adaptive design with weibull distribution. J Biopharm Stat 2012;22:773-784.
27. Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive assessment of fibrosis in patients with nonalcoholic fatty liver disease. Int J Endocrinol 2015;2015:343828.
28. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873.
29. Pagadala MR, McCullough AJ. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liv Dis 2012;16:487-504.
30. European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. Committee for Medicinal Products for Human Use (CHMP). CHMP/EWP/2459/02. Available at: http://www.emea.europa.eu. Published October 18, 2007.
31. Ando Y, Hirakawa A, Uyama Y. Adaptive clinical trials for new drug applications in Japan. Eur Neuropsychopharmacol 2011;21:175-179.